Abstract
Dopamine β-monooxygenase (DBM) catalyses the conversion of dopamine to norepinephrine in the catecholamine biosynthetic pathway. The substrate specificity of DBM is wide and the enzyme is capable of performing a variety of oxidations. While the crystal structure of DBM is not yet available, various indirect data allow insight into the enzymes machinery. Considered an attractive therapeutic target for the treatment of hypertension and congestive heart failure, DBM and its inhibitors have received attention by medicinal chemists over the last four decades. Although several QSAR models for DBM inhibitors have been generated, these models are actually unable to explain the exceptionally high potency of the latest generation of inhibitors.
Keywords: Dopamine β-monooxygenase, dopamine β-hydroxylase, inhibitor, imidazolethione, nepicastat, BIA 5-453, CHF
Current Enzyme Inhibition
Title: Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors
Volume: 5 Issue: 1
Author(s): Alexandre Beliaev, Humberto Ferreira, David A. Learmonth and Patricio Soares-da-Silva
Affiliation:
Keywords: Dopamine β-monooxygenase, dopamine β-hydroxylase, inhibitor, imidazolethione, nepicastat, BIA 5-453, CHF
Abstract: Dopamine β-monooxygenase (DBM) catalyses the conversion of dopamine to norepinephrine in the catecholamine biosynthetic pathway. The substrate specificity of DBM is wide and the enzyme is capable of performing a variety of oxidations. While the crystal structure of DBM is not yet available, various indirect data allow insight into the enzymes machinery. Considered an attractive therapeutic target for the treatment of hypertension and congestive heart failure, DBM and its inhibitors have received attention by medicinal chemists over the last four decades. Although several QSAR models for DBM inhibitors have been generated, these models are actually unable to explain the exceptionally high potency of the latest generation of inhibitors.
Export Options
About this article
Cite this article as:
Beliaev Alexandre, Ferreira Humberto, Learmonth A. David and Soares-da-Silva Patricio, Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors, Current Enzyme Inhibition 2009; 5 (1) . https://dx.doi.org/10.2174/157340809787314265
DOI https://dx.doi.org/10.2174/157340809787314265 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Adrenomedullin in Cardiovascular Disease: A Useful Biomarker, its Pathological Roles and Therapeutic Application
Current Protein & Peptide Science The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Mouse and Human Embryonic Stem Cells: Can They Improve Human Health by Preventing Disease?
Current Topics in Medicinal Chemistry Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications
Current Topics in Medicinal Chemistry Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Status Epilepticus: An Overview
Current Drug Metabolism PET Imaging and Coronary Circulatory Function: Non-Invasive Mechanistic Insights and Cardiovascular Prognosis
Current Cardiology Reviews Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Cachexia and Oxidative Stress in Cancer: An Innovative Therapeutic Management
Current Pharmaceutical Design Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options
Current Medicinal Chemistry Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design